Kanto CML Study Group: Clinical Trials

4 trials sponsored by Kanto CML Study Group, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 unknown. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Unknown 1

Follow Kanto CML Study Group: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial
dasatinib - Myelogenous Leukemia, Chronic, Chronic Phase
Phase 2UnknownKanto CML Study Group1002012-11-012013-06-27
Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myelogenous Leukemia, Chronic, Chronic Phase
UnknownKanto CML Study Group402011-07-012011-11-03
A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib
dasatinib - Chronic Myeloid Leukemia
Phase 2CompletedKanto CML Study Group212011-04-012015-09-15
A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia
dasatinib - Chronic Myeloid Leukemia
Phase 2CompletedKanto CML Study Group652009-03-012015-09-15

Conditions studied

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3)  ·  Leukemia, Myeloid, Chronic-Phase (3)

Interventions

Dasatinib (3)

Countries

Japan (4)

Top investigators

Chikashi Yoshida, MD, PhD (1)  ·  Hisashi Sakamaki, MD.PhD (1)

Results publications

PMID 25501110, PMID 25530131, PMID 26103598